Hormone replacement therapy (HRT) replaces estrogen and progesterone that your body stops producing during menopause, offering effective relief from symptoms and improving daily life for many women. Clarifying the different types helps women choose the most suitable option.
Estrogen-only HRT is prescribed for women who have had a hysterectomy, as they no longer need progesterone to protect the uterine lining. This type of HRT effectively alleviates vasomotor symptoms, such as hot flashes and night sweats.
Combined HRT is the standard option for women who still have their uterus. It combines estrogen with progesterone to prevent the uterine lining from thickening abnormally. This therapy is available in two forms: sequential (where progesterone is taken for part of the cycle) and continuous combined (where both hormones are taken daily).
Bioidentical HRT uses 17 beta-oestradiol, which the body naturally produces. Widely available on prescription and considered the safest and most evidence-backed form of HRT currently.
Compounded bioidentical HRT is mixed at a pharmacy to a custom formula. Not well-studied, and many clinicians do not recommend them due to uncertainty around long-term safety and quality consistency.
How you take HRT matters as much as which type you take.
| Patches | Thin adhesive patches are applied to the skin every few days. Release hormones steadily into the bloodstream at a consistent level. Carry no increased risk of blood clots, making them the preferred delivery method for most women. |
| Gels | Applied daily to the skin, usually on the arm or thigh. Absorbed directly into the bloodstream. Offer flexible daily dosing and are a good option if you prefer not to wear a patch. |
| Creams | Applied to the skin similarly to gels. Effective for transdermal absorption and a good option for women who prefer a cream texture over a gel or patch. |
| Pills (oral tablets) | Oral tablets are taken daily and effectively relieve symptoms, but have a slightly higher risk of blood clots due to liver processing, which is important for women to consider when choosing a delivery method. |
Which is safest?
Finding the right type and delivery method is a personal process, and your doctor will adjust your prescription based on how you respond, ensuring you feel supported and valued in your treatment choices.
Benefits of HRT: – what the evidence shows
Symptom relief-vasomotor: – HRT is the most effective treatment available for hot flushes and night sweats, which affect 60-80% of postmenopausal women. Oestrogen is the most effective treatment for vasomotor symptoms, with HRT being most beneficial when started before age 60 or within 10 years of menopause. Most women notice significant improvement within a few weeks of starting treatment.
Symptom relief-Mood, sleep & libido: – Other menopause-related symptoms, including mood swings, sleep disturbance, sexual dysfunction, and muscle discomfort, may also improve with HRT, making it a wide-ranging treatment rather than one that targets only physical symptoms. Many women report better concentration, energy, and overall quality of life.
Symptoms relief-genitourinary: – HRT is the first-line treatment for genitourinary syndrome of menopause, including vaginal dryness, discomfort during sex, and recurrent urinary tract infections, particularly with low-dose local vaginal oestrogen preparations. These symptoms often worsen over time without treatment, and local oestrogen can be used long-term with a very low systemic absorption.
Bone health: – HRT is effective in preventing bone loss associated with menopause and in reducing the incidence of all osteoporosis-related fractures, including those of the vertebrae and hip. A 2025 systematic review confirmed that postmenopausal women on HRT showed greater improvements in bone mineral density than those on exercise therapy alone, with a decreased risk of fracture at the hip and spine.
Cardiovascular health: – The timing hypothesis proposes that HRT initiated within 10 years of menopause onset or before age 60 may confer cardiovascular benefit. At the same time, later initiation may increase cardiovascular risk. Long-term benefits of HRT include prevention of metabolic abnormalities in lipid and carbohydrate metabolism and mitigation of increased cardiovascular risk associated with declining hormone levels.
Cognitive health: – Evidence here is promising but still evolving. Research findings regarding the impact of HRT on cognition and dementia are considerably less reliable than for other benefits and require further research. However, some studies suggest a protective effect when HRT is started early in the menopause transition. This remains an active area of clinical investigation.
In May 2024, WHI researchers published their 20-year follow-up data showing no increase in deaths from breast cancer or cardiovascular disease in women who participated in the original trials, updating earlier concerns that had led many women to stop or avoid HRT unnecessarily.
Risk: – what the research actually says
| Risk Area | What the evidence shows |
| Breast cancer | HRT can lead to little or no increase in breast cancer risk, and the risk depends on the duration and composition of the HRT, decreasing after you stop treatment. There was no increase in breast cancer risk for HRT taken for less than a year, and risks were extremely low with oestrogen-only HRT. For most women, the absolute increase in risk is small and managing menopause well has real long-term benefits beyond symptom relief. |
| Combined vs. oestrogen-only HRT | Oestrogen-only HRT carries an extremely low breast cancer risk but can only be taken if you’ve had a hysterectomy. If you still have your uterus, you’ll take combined HRT, which contains both oestrogen and progesterone and carries a slightly higher risk than oestrogen alone. The type of progestogen your doctor prescribes also matters; micronised progesterone appears to carry a lower risk than synthetic progestogens. |
The WHI study: – why it caused confusion
After the WHI results were published in 2002, HRT prescriptions dropped by approximately 40% within a year, driven largely by fear rather than a full understanding of the data. The trial had significant design limitations, including studying older women using synthetic hormones at higher doses than are prescribed today. Its findings don’t reflect the modern HRT your doctors would offer you now.
Updated 20-year evidence: –
Even accepting the WHI’s claims of increased risk, that increase amounts to one additional case of breast cancer for every 1,000 women treated per year, with no increase in the risk of dying from breast cancer. As longer-term follow-up data have emerged, the evidence has become considerably more reassuring for women considering HRT.
Who should avoid HRT?
HRT is contraindicated if you have a personal history of breast cancer, though it can be individually considered after a thorough risk-benefit assessment when non-hormonal options haven’t helped. Other reasons to avoid it include active liver disease, unexplained vaginal bleeding, and a history of oestrogen-sensitive cancers. Your specialist will assess your individual profile before making any recommendations.
Your risk with HRT depends on many factors, like the dose, type, duration, and route of administration, all of which play a role, and your profile should be reassessed periodically over time. What works well and safely for one woman may not be right for another, which is exactly why a personalised approach with your doctors always gives you the clearest picture.
Who is a good candidate?
| Factor | What this means for you |
| Age and timing | The best candidates to take hormone replacement therapy are females who are under the age of 60 or have experienced their natural menopause within the past ten years and have a low risk for heart disease and breast cancer. Those who begin to take hormones closer to the onset of their menopause have greater responses to HRT; therefore, this is called the timing hypothesis, which states that the longer you wait to take HRT, the less effective it will be. If you are 50 years of age or older and have had symptoms, you are in a good position to receive benefits from hormone replacement therapy. |
| Symptoms severity | Menopausal hormone replacement therapy (HRT) isn’t just for those who are having extreme difficulty with their symptoms; rather, the most common use of HRT is to relieve symptoms that are significantly impacting one’s daily functioning. Symptoms can range from night sweats and mood swings to difficulties sleeping and declining bone density. By weighing the severity and frequency of each symptom, one can decide if HRT is right for them. If symptoms are mild or easily managed, it may make sense to pursue non-hormonal methods first. |
| Health history | Your personal and family medical history shapes whether HRT is appropriate for you. Key elements your doctor will assess include lifestyle factors such as smoking and alcohol intake, mental health history, and personal or family history of breast cancer, cardiovascular disease, osteoporosis, diabetes, thyroid disorders, and venous thromboembolism. This isn’t about ruling you out; it’s about finding the safest for your individual profile. |
| Women with chronic conditions | You are not necessarily disqualified from HRT just because you have a long-term condition. When managing menopause combined with diabetes, hypertension, or obesity, the best form of HRT for women is a transdermal oestrogen patch/gel (rather than oral tablets) as there is less effect on clotting factor levels, blood pressure levels, triglyceride levels, and inflammatory markers than with oral tablets. Your doctor will write you a prescription specifically designed to complement your current health care management program. |
| Early menopause | HRT is very important if you stop having periods before age 40 for your long-term health, as well as to help you with your symptoms. The early loss of oestrogen at an early age dramatically increases your risk of cardiovascular disease. Women who experience menopause prior to age 40 will be at increased risk of heart disease if they do not take HRT. This is why it is usually recommended that those with early menopause take HRT until they reach the average age of the natural menopause event. |
There is no fixed age at which HRT must be stopped. Long-term use may be appropriate for healthy women with ongoing symptoms or an elevated risk of fracture, and duration should depend on your symptoms, health status, and personal preference. Your doctor will review your prescription periodically and adjust it as your needs change over time.
How to start HRT
Visiting your general practitioner (GP) is typically the most common first step in getting treated for menopause. They will take your full medical history and will evaluate what is currently happening to determine an appropriate HRT option for you. If you have complex issues, or existing medical conditions, or if you just want to have an opinion from a specialist right away, you can request to be referred to a menopause clinic or an expert gynaecologist for menopause treatment. There is no reason to wait to visit until your life feels unbearable. By speaking with your GP earlier, you have more treatment options available.
Your doctor will assess your blood pressure, weight, and personal/family history of medical conditions before beginning treatment for you. Baseline testing on your hormone levels will be done before starting HRT, as well as a few follow-up tests in the first 3 months of treatment to ensure that your hormone levels are within therapeutic range and that you are responding to the treatment in a safe manner. A complete health assessment typically includes at least 2 of the following tests in addition to your hormone assessment: thyroid function and a cholesterol test.
Some women may experience mild to moderate side effects during the first few days of starting their hormone therapy, while their bodies adapt to the new hormones. Mild nausea, breast tenderness, bloating, and headaches are very common side effects in the early days of treatment but are not an indication that HRT is ineffective for these women; the side effects will usually subside within 4 to 6 weeks after starting HRT. Hot flushes and night sweats will typically improve first, and sleep, mood, and energy levels usually begin to improve thereafter.
Women should give their prescription 3 to 6 months before evaluating how well it is working; however, they must attend their 3-month follow-up appointment so that the prescriber has the opportunity to make any necessary changes to the dose or method of administration prescribed to the woman. There may be an adjustment period while determining an appropriate dose and method of delivery, but the majority of women will find what works best for them.
HRT in Singapore
The level of access to hormone replacement therapy (HRT) in Singapore is good in both public and private facilities, and there are many more choices for women than they realise.
Singapore has an average age of around 49 years at natural menopause, and studies show that more than half of all women in midlife experience moderate to severe symptoms from menopause, which impacts their lives daily. However, many women do not access treatment for menopause due to uncertainty regarding how to start and not realising how accessible treatment for menopause is.
The most affordable access to HRT is through public hospitals. KKH and SGH each operate dedicated menopause clinics, treating women with personalised HRT options, bone density testing, and hormone assessments. The services at both facilities are subsidised for women who are referred by a polyclinic. KKH has an excellent reputation for providing specialist care at affordable costs. At the same time, SGH’s Menopause Clinic offers personalised treatment, including hormonal therapy, psychological support, and osteoporosis screening, with expertise in medicine.
When looking for private health care and shorter wait times, a few clinics can be considered. There is the Raffles Women’s Centre, which provides comprehensive menopause care, including HRT and bio-identical hormones; Osler Health at the Raffles Hotel Arcade and Star Vista offers evidence-based, in-depth women’s health/HRT; Aster Gynaecology at Mount Elizabeth Novena, with Dr Ng Kai Lyn heading the practice, has a special clinical interest in menopause management.
ATA Medical’s appointments begin at approximately SGD $65.40 (consultation only), and HRT therapy costs can range between SGD $35.97 and $75.21 (all therapy-related expenses are for hormone testing/second visit); therefore, your total expense will depend on what HRT type is prescribed, plus the specific monitoring recommended across different clinics.
Frequently Asked Questions
Reference:
Arnautu, A. M., Nimigean, V. R., Nacea-Radu, C. A., Tilici, D. M., & Paun, D. L. (2025). Menopausal Hormone Therapy—Risks, Benefits and Emerging Options: A Narrative Review. International Journal of Molecular Sciences, 26(22), 11098. https://doi.org/10.3390/ijms262211098
D’Alonzo, M., Bounous, V. E., Villa, M., & Biglia, N. (2019). Current Evidence of the Oncological Benefit-Risk Profile of Hormone Replacement Therapy. Medicina, 55(9), 573. https://doi.org/10.3390/medicina55090573
Deighan, A., Bikkani, A., Develen, C., & Faubion, S. S. (2026). NextGen Now: Building a sustainable future for menopause care. A transformative initiative from The Menopause Society. Menopause, 33(7), 759. https://doi.org/10.1097/GME.0000000000002824
Distler, K. R., Kappers, D., & Hollingsworth, J. C. (n.d.). Patients’ Concerns for Hormone-Replacement Therapy for Menopause. Cureus, 17(11), e96709. https://doi.org/10.7759/cureus.96709
Fillon, M. (2024). The association between menopausal hormone therapy and breast cancer remains unsettled. CA: A Cancer Journal for Clinicians, 74(3), 210–212. https://doi.org/10.3322/caac.21843
Gregson, C. L., Armstrong, D. J., Avgerinou, C., Bowden, J., Cooper, C., Douglas, L., Edwards, J., Gittoes, N. J. L., Harvey, N. C., Kanis, J. A., Leyland, S., Low, R., McCloskey, E., Moss, K., Parker, J., Paskins, Z., Poole, K., Reid, D. M., Stone, M., … Compston, J. (2025). The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis, 20(1), 119. https://doi.org/10.1007/s11657-025-01588-3
Huang, X., & Hua, Y. (2026). Erratum: Association between reproductive span and postmenopausal metabolic syndrome: a cross-sectional study in China. Menopause, 33(7), 861. https://doi.org/10.1097/GME.0000000000002875
Khalifey, H. T., Mahereen, R., Adwan, R., Chahine, R., Kaidali, M., Mirza, S. F., Tullah, S. N., Shaikh, S., Hammad, S., & Sukkarieh, H. H. (n.d.). The impact of hormone replacement therapy on cardiovascular health in postmenopausal women: A narrative review. Frontiers in Reproductive Health, 8, 1745210. https://doi.org/10.3389/frph.2026.1745210
Kurabayash, T., Nagai, K., Hayashi, K., Yasui, T., Takamatsu, K., & Ideno, Y. (2026). Importance of changes in body mass index from adolescence to middle age as a risk factor for osteoporosis: The Japan Nurses’ Health Study. Menopause, 33(7), 767. https://doi.org/10.1097/GME.0000000000002740
Lemos, M. J., Queiroz, L. F., Diniz, A. F., Longo da Silva, C. M., dos Santos, P. L., de Oliveira Gomide, P., Ferraz, J. M., & De Marco Novellino, A. M. (2026). Intravaginal dehydroepiandrosterone for the treatment of vulvovaginal atrophy: A systematic review and meta-analysis. Menopause, 33(7), 852. https://doi.org/10.1097/GME.0000000000002736
McClung, M. R. (2026). Low body mass index: An early warning sign for osteoporosis. Menopause, 33(7), 762. https://doi.org/10.1097/GME.0000000000002825
New study finds early hormone replacement therapy reduces risk of osteoporosis and fractures for older women. (2026, March 2). AAOS 2026 Annual Meeting Press Kit. https://aaos-annualmeeting-presskit.org/2026/research-news/new-study-finds-early-hormone-replacement-therapy-reduces-risk-of-osteoporosis-and-fractures-for-older-women/
NICE. (2015, November 12). Overview | Menopause: Identification and management | Guidance | NICE. https://www.nice.org.uk/guidance/ng23
Panay, N. (2026). Practical evidence-based diagnosis and management of premature ovarian insufficiency. Menopause, 33(7), 841. https://doi.org/10.1097/GME.0000000000002856
Qiu, C., Liu, X., & Zhao, M. (2026). Letter: Associations between vasomotor symptoms, sleep disturbances, and frequent mood changes individually and within symptom groups across the menopausal transition and early postmenopause: observations from the Study of Women’s Health Across the Nation. Menopause, 33(7), 859. https://doi.org/10.1097/GME.0000000000002799
Treviño, M., Leiker, P., Palnati, S. R., & Bhakta, S. (n.d.). Comparative Effects of Hormone Replacement Therapy and Exercise on Bone Health in Postmenopausal Women: A Systematic Review. Cureus, 17(12), e99210. https://doi.org/10.7759/cureus.99210
Zhu, Z., Zhu, L., Song, B., Wang, C., Cao, Y., & Li, G. (2026). Postmenopausal hypoactive sexual desire disorder: Ongoing challenges. Menopause, 33(7), 844. https://doi.org/10.1097/GME.0000000000002729
Anna Haotanto is the Founder of Zora Health and a passionate advocate for women’s empowerment. Anna’s personal experiences with egg-freezing, PCOS, perimenopause and the challenges of fertility have fueled her mission to provide high-quality information, financing, and support to help women and couples navigate their fertility journeys with confidence. She is also recognised for her achievements in finance, entrepreneurship, and women’s empowerment, and has been featured in various media outlets. You can also follow her on Linkedin or Instagram.
